{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:14:55Z","timestamp":1753359295367},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T00:00:00Z","timestamp":1437523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf - Case Rep"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40800-015-0012-6","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T11:25:06Z","timestamp":1437477906000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction"],"prefix":"10.1007","volume":"2","author":[{"given":"Yusuf Haydar","family":"Ertekin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkay","family":"Yakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fclya","family":"Ertekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015feg\u00fcl","family":"Uluda\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,22]]},"reference":[{"key":"12_CR1","first-page":"272","volume":"67","author":"FY Khan","year":"2009","unstructured":"Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67:272\u201383.","journal-title":"Neth J Med"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2169\/internalmedicine.50.4484","volume":"50","author":"Y Oshima","year":"2011","unstructured":"Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8610 cases reported to the U.S. Food and Drug Administration. Intern Med. 2011;50:845\u201353.","journal-title":"Intern Med"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00228-006-0131-1","volume":"62","author":"DWJ Clark","year":"2006","unstructured":"Clark DWJ, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62:473\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00000441-199608000-00008","volume":"312","author":"FG Delrio","year":"1996","unstructured":"Delrio FG, Park Y, Herzlich B, Grob D. Case report: diclofenac-induced rhabdomyolysis. Am J Med Sci. 1996;312:95\u20137.","journal-title":"Am J Med Sci"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00113-004-0874-z","volume":"108","author":"K Knobloch","year":"2005","unstructured":"Knobloch K, et al. Rhabdomyolysis after administration of diclofenac. Unfallchirurg. 2005;108:415\u20137.","journal-title":"Unfallchirurg"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jbspin.2004.04.010","volume":"72","author":"S Guis","year":"2005","unstructured":"Guis S, Mattei J-P, Cozzone PJ, Bendahan D. Pathophysiology and clinical presentations of rhabdomyolysis. Jt Bone Spine. 2005;72:382\u201391.","journal-title":"Jt Bone Spine"},{"key":"12_CR7","unstructured":"Y\u00fckse N. Cytochrome P450 enzyme system and drug interactions. [Sitokrom P450 Enzim Sistemi ve \u0130la\u00e7 Etkile\u015fmeleri]. Klin. Psikiyatr. 2001;5\u201316. Available from: http:\/\/www.klinikpsikiyatri.org\/files\/journals\/1\/305.pdf . Accessed 16 Aug 2014."},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/PL00000897","volume":"58","author":"P Anzenbacher","year":"2001","unstructured":"Anzenbacher P, Anzenbacherov\u00e1 E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58:737\u201347.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"12_CR9","first-page":"203","volume":"16","author":"K \u00dcney","year":"2006","unstructured":"\u00dcney K, Tra\u015f B. Use of in vivo probe drugs in the determination of activities of drug metabolizing enzymes. Genel Tip Derg. 2006;16(4):203\u201311.","journal-title":"Genel Tip Derg"},{"key":"12_CR10","first-page":"152","volume":"34","author":"H Bliesath","year":"1996","unstructured":"Bliesath H, Huber R, Steinijans VW, et al. Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther. 1996;34:152\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"X-Q Li","year":"2004","unstructured":"Li X-Q, Andersson TB, Ahlstr\u00f6m M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821\u20137.","journal-title":"Drug Metab Dispos"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.toxlet.2004.12.008","volume":"156","author":"D Balayssac","year":"2005","unstructured":"Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett. 2005;156:319\u201329.","journal-title":"Toxicol Lett"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","volume":"364","author":"C Pauli-Magnus","year":"2014","unstructured":"Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2014;364:551\u20137.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","volume":"11","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zhang YD, Zhao P, Huang S-M. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11:300\u20136.","journal-title":"AAPS J."}],"container-title":["Drug Safety - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40800-015-0012-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-015-0012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-015-0012-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:13:26Z","timestamp":1551204806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40800-015-0012-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,22]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s40800-015-0012-6","relation":{},"ISSN":["2199-1162","2198-977X"],"issn-type":[{"value":"2199-1162","type":"print"},{"value":"2198-977X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,22]]},"article-number":"10"}}